- Markets
- Trading
- VIVANZA
VIVANZA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vivanza Biosciences Approves Borrowing To Be Increased To 200 Million Rupees
June 30 (Reuters) - Vivanza Biosciences Ltd VIVN.BO:
APPROVED BORROWING TO BE INCREASED TO 200 MILLION RUPEES
Source text for Eikon: ID:nBSE7k1p7d
Further company coverage: VIVN.BO
(([email protected];))
June 30 (Reuters) - Vivanza Biosciences Ltd VIVN.BO:
APPROVED BORROWING TO BE INCREASED TO 200 MILLION RUPEES
Source text for Eikon: ID:nBSE7k1p7d
Further company coverage: VIVN.BO
(([email protected];))
Vivanza Biosciences Names Jayendra Mehta As Managing Director
April 25 (Reuters) - Vivanza Biosciences Ltd VIVN.BO:
NAMES JAYENDRA MEHTA AS MANAGING DIRECTOR
MD GIRISH BHATT RESIGNS
Source text for Eikon: ID:nBSE8YMY4S
Further company coverage: VIVN.BO
(([email protected];))
April 25 (Reuters) - Vivanza Biosciences Ltd VIVN.BO:
NAMES JAYENDRA MEHTA AS MANAGING DIRECTOR
MD GIRISH BHATT RESIGNS
Source text for Eikon: ID:nBSE8YMY4S
Further company coverage: VIVN.BO
(([email protected];))
Events:
Split
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vivanza Biosciences do?
Vivanza Biosciences Ltd, established in 1982, specializes in trading pharmaceutical products, offering a range of traded pharmaceutical products and services.
Who are the competitors of Vivanza Biosciences?
Vivanza Biosciences major competitors are Devine Impex, AMS Polymers, Sun Retail, Universal OfficeAuto, Tiaan Consumer, Ambassador IntraHold, Ind Link Chain Mfg. Market Cap of Vivanza Biosciences is ₹9 Crs. While the median market cap of its peers are ₹9 Crs.
Is Vivanza Biosciences financially stable compared to its competitors?
Vivanza Biosciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Vivanza Biosciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vivanza Biosciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vivanza Biosciences allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Vivanza Biosciences balance sheet?
Balance sheet of Vivanza Biosciences is moderately strong.
Is the profitablity of Vivanza Biosciences improving?
The profit is oscillating. The profit of Vivanza Biosciences is ₹0.55 Crs for Mar 2024, ₹0.6 Crs for Mar 2023 and ₹0.33 Crs for Mar 2022
Is the debt of Vivanza Biosciences increasing or decreasing?
Yes, The debt of Vivanza Biosciences is increasing. Latest debt of Vivanza Biosciences is ₹6.07 Crs as of Sep-24. This is greater than Mar-24 when it was ₹5 Crs.
Is Vivanza Biosciences stock expensive?
Vivanza Biosciences is not expensive. Latest PE of Vivanza Biosciences is 0.0, while 3 year average PE is 96.93. Also latest EV/EBITDA of Vivanza Biosciences is 33.05 while 3yr average is 140.
Has the share price of Vivanza Biosciences grown faster than its competition?
Vivanza Biosciences has given lower returns compared to its competitors. Vivanza Biosciences has grown at ~-30.99% over the last 4yrs while peers have grown at a median rate of 27.03%
Is the promoter bullish about Vivanza Biosciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Vivanza Biosciences is 20.02% and last quarter promoter holding is 20.02%.
Are mutual funds buying/selling Vivanza Biosciences?
There is Insufficient data to gauge this.